Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
CRISPR Therapeutics AG (CRSP) had Stock-Based Compensation of $72.50M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$0.86M |
|
$-130.61M |
|
-- |
|
$0.86M |
|
$155.63M |
|
$-154.76M |
|
$24.77M |
|
$-130.00M |
|
$-130.00M |
|
$-130.61M |
|
$-130.61M |
|
$-130.61M |
|
$-130.61M |
|
$-154.76M |
|
$-149.10M |
|
89.92M |
|
89.92M |
|
$-1.32 |
|
$-1.32 |
|
| Balance Sheet Financials | |
$1.99B |
|
$115.85M |
|
$279.57M |
|
$2.27B |
|
$149.12M |
|
-- |
|
$194.31M |
|
$343.43M |
|
$1.92B |
|
$1.92B |
|
$1.92B |
|
95.89M |
|
| Cash Flow Statement Financials | |
$-345.01M |
|
$-31.80M |
|
$426.03M |
|
$309.78M |
|
$359.08M |
|
$49.30M |
|
|
Stock-Based Compensation |
$72.50M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.32 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-17912.50% |
|
-17912.49% |
|
-- |
|
-15046.19% |
|
-15117.24% |
|
$-345.93M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-6.80% |
|
-6.80% |
|
-5.77% |
|
-6.80% |
|
$20.04 |
|
$-3.85 |
|
$-3.84 |
|